CTLA4 and urothelial carcinoma: In patients with urothelial carcinoma, treatment with anti-CTLA-4 preoperatively resulted in increased frequency of CD4 + ICOShi T cells, which was then retrospectively shown to correlate with overall survival for metastatic melanoma patients [154].